Protagonist Therapeutics, Inc. (PTGX) — Analyst outlook / Analyst consensus target is. Based on 26 analyst ratings, the consensus is bullish — 25 Buy, 1 Hold.
The consensus price target is $113.60 (low: $108.00, high: $121.00), representing an upside of 8.5% from the current price $104.72.
Analysts estimate Earnings Per Share (EPS) of $3.45 and revenue of $0.38B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $4.47 vs est $3.45 (beat +29.5%). 2025: actual $-2.05 vs est $-1.96 (missed -4.3%). Analyst accuracy: 87%.
PTGX Stock — 12-Month Price Forecast
$113.60
▲ +8.48% Upside
Average Price Target
Based on 26 Wall Street analysts offering 12-month price targets for Protagonist Therapeutics, Inc., the average price target is $113.60, with a high forecast of $121.00, and a low forecast of $108.00.
The average price target represents a +8.48% change from the last price of $104.72.
Highest Price Target
$121.00
Average Price Target
$113.60
Lowest Price Target
$108.00
PTGX Analyst Ratings
Buy
Based on 26 analysts giving stock ratings to Protagonist Therapeutics, Inc. in the past 3 months
EPS Estimates — PTGX
87%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $4.47
vs Est $3.45
▲ 22.8% off
2025
Actual –$2.05
vs Est –$1.96
▼ 4.2% off
Profitability Outlook
Company has mixed profitability — some years profitable, some at a loss. Analysts expect the company to turn profitable.
Revenue Estimates — PTGX
93%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.434B
vs Est $0.382B
▲ 12.1% off
2025
Actual $0.046B
vs Est $0.047B
▼ 2.2% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
